Piper Sandler analyst Jason Bednar raised the firm’s price target on Merit Medical (MMSI) to $110 from $106 and keeps an Overweight rating on the shares. The firm is updating its Merit Medical model for several recent items, including the Biolife transaction announced earlier this week and the segment revenue recasting that was done effective Q1.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $112 from $108 at Canaccord
- Merit Medical price target raised to $108 from $106 at Wells Fargo
- Merit Medical Acquires Biolife Delaware for $120 Million
- Merit Medical’s Strategic Acquisition of Biolife Delaware: A Long-Term Growth Catalyst
- Merit Medical adjusts FY25 EPS view to $3.28-$3.41 from $3.29-$3.42